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Abstract
Fibroblast growth factor (FGF) and epidermal growth factor (EGF) are critical for the development of the nervous system. We
previously discovered that FGF2 and EGF had opposite effects on motor neuron differentiation from human fetal neural
stem cells (hNSCs), but the underlying mechanisms remain unclear. Here, we show that FGF2 and EGF differentially affect
the temporal patterns of Akt and glycogen synthase kinase 3 beta (GSK3b) activation. High levels of phosphatidylinositol 3-
kinase (PI3K)/Akt activation accompanied with GSK3b inactivation result in reduction of the motor neuron transcription
factor HB9. Inhibition of PI3K/Akt by chemical inhibitors or RNA interference or overexpression of a constitutively active
form of GSK3b enhances HB9 expression. Consequently, PI3K inhibition increases hNSCs differentiation into HB9
+/
microtubule-associated protein 2 (MAP2)
+ motor neurons in vitro. More importantly, blocking PI3K not only enhances motor
neuron differentiation from hNSCs grafted into the ventral horn of adult rat spinal cords, but also permits ectopic
generation of motor neurons in the dorsal horn by overriding environmental influences. Our data suggest that FGF2 and
EGF affect the motor neuron fate decision in hNSCs differently through a fine tuning of the PI3K/AKT/GSK3b pathway, and
that manipulation of this pathway can enhance motor neuron generation.
Citation: Ojeda L, Gao J, Hooten KG, Wang E, Thonhoff JR, et al. (2011) Critical Role of PI3K/Akt/GSK3b in Motoneuron Specification from Human Neural Stem
Cells in Response to FGF2 and EGF. PLoS ONE 6(8): e23414. doi:10.1371/journal.pone.0023414
Editor: Mai Har Sham, The University of Hong Kong, China
Received March 10, 2011; Accepted July 16, 2011; Published August 24, 2011
Copyright:  2011 Ojeda et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the John S. Dunn Research Foundation, the Cullen Foundation, the TIRR Foundation, the Gillson Longenbaugh
Foundation, the Moody Foundation, and the NIH (F30NS060387 to J.R.T. and R01 CA133429 to T.G.). The funders had no role in study design, data collectiona n d
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: piwu@utmb.edu
. These authors contributed equally to this work.
¤ Current address: Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, United States of America
Introduction
Neural stem cells (NSCs) can self-renew and differentiate into all
three neural lineages (neurons, astrocytes and oligodendrocytes).
The final fate that NSCs will adopt depends on the activation of
specific signaling pathways, which are stimulated by different
ligands, including growth factors [1–3]. Among those growth
factors, basic fibroblast growth factor (bFGF or FGF2) plays
important roles in the development of the central nervous system,
neuronal repair and survival, proliferation and neurogenesis in the
developing cerebral cortex, and other neural related functions [4–
8]. In addition, FGF2 has been extensively used for the growth of
rodent, primate and human NSCs (hNSCs) in culture. Another
growth factor commonly used in culturing hNSCs is epidermal
growth factor (EGF). Besides their proliferation role, the two
growth factors also modulate the plasticity of hNSCs [9]. Human
NSCs do not generate spinal motor neurons (MNs) after
differentiation. However, when hNSCs are primed in the presence
of FGF2, they express a higher level of MN-specific transcription
factor HB9 and generate more MNs than after priming with EGF,
leukemia inhibitory factor (LIF) or EGF plus LIF. Thus, exposure
to distinct growth factors elicits different cell fates. Interestingly,
FGF2 and EGF activate some common signaling pathways [10],
which raises the question on how these factors lead to different
phenotypic outcomes. One possibility is that these different growth
factors activate the same canonical signaling but different non-
canonical pathways [11]. A second possibility is that they activate
the same pathways but with different intensities of activation (e.g.
phosphorylation level of downstream proteins) or different
duration of activation (e.g. the time that the proteins in the
pathway remain phosphorylated) [12]. Knowledge of how these
factors control MN differentiation from NSCs may have profound
significance in therapies for MN disorders, such as amyotrophic
lateral sclerosis and spinal cord injury, where MN replacement
may be one of the ultimate choices. Unfortunately in many studies
using stem cell transplantation, the only benefits observed are due
to stem cell-released trophic factors or decreased inflammation
that promotes survival of endogenous MNs [13–16]. On the other
hand, several groups including us have obtained spinal MNs from
either embryonic stem cells or neural stem cells of human or
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becoming MNs vary from 0.5% to 50% [17], and the underlying
molecular mechanisms controlling MN fate specification in
response to different growth factors remain elusive.
In this study we asked how FGF and EGF differentially
influence the same cell signaling pathways on the same target cells
(hNSCs) to achieve different fates. Surprisingly, we found that the
PI3K (phosphatidylinositol 3-kinase)/Akt/GSK3b (Glycogen syn-
thase kinase 3b) pathway modulates the decision of hNSCs to
become MNs, both in vitro and after transplantation into the rat
spinal cord, even in areas that normally do not possess MNs. This
discovery could provide insights into stem cell-based therapies to
replace MNs lost in diseases.
Results
FGF2 and EGF differentially affect the temporal pattern of
Akt and GSK3b phosphorylation in hNSCs
We have previously discovered that priming with FGF2 plus
laminin (FL) endowed hNSCs with the potential to differentiate
into MNs, whereas EGF/laminin or EGF plus LIF/laminin (ELL)
priming inhibited MN formation [9]. LIF alone showed no effect.
The phenotypic differences between FGF2 and EGF were
accompanied by different levels of Akt phosphorylation at the
end of the 4-day priming period [9]. It is known that activation of
the FGF and EGF receptors, FGFR and EGFR, respectively,
could both lead to the activation of the PI3K/Akt pathway that
negatively regulates GSK3b [20]. However, it is unknown whether
the different levels of Akt activation contribute to the differential
MN generation of hNSCs in response to FGF2 and EGF. Thus,
we first compared the temporal phosphorylation pattern of the Akt
signaling pathway in hNSCs during FL or ELL priming. FL- and
ELL-primed cells, in addition to the morphological differences
(uniform and multipolar in FL vs. heterogeneous and spindle
shape in ELL, Fig. 1A–B), showed different phosphorylation
patterns of Akt and GSK3b (Fig. 1C–D). The 40-min (0.7 hr) was
chosen as the earliest time point in this study to ensure the
attachment of hNSC neurospheres required for priming. While FL
priming consistently maintained lower levels of phosphorylated
Akt Ser473, ELL promoted higher phosphorylation of Akt during
the first two hours of priming (Fig. 1C) and thus increased Akt’s
activity. The latter was further evidenced by a higher phosphor-
ylation of the downstream GSK3b Ser9 (Fig. 1D). In contrast, FL
reduced GSK3b-Ser9 phosphorylation that would increase its
activity, especially during the early phase of priming. We also
analyzed the phosphorylation of GSK3b at Tyr216 (which
activates GSK3b activity), and found it being phosphorylated in
both priming treatments (data not shown). Thus, GSK3b is
negatively regulated by Akt via Ser9 phosphorylation, with ELL
priming evoking less GSK3b activity than FL priming.
High levels of PI3K/Akt activation inhibit MN
differentiation from hNSCs
Since the temporal activation patterns of the examined kinases
were different between FL and ELL (Fig. 1), we asked if their
activities have any impact on the MN induction from hNSCs. To
this end, we systematically inhibited these kinases and analyzed the
effects of the inhibitions on the expression of the MN transcription
factor HB9. The initial focus was to disrupt the PI3K/Akt
pathway using both RNA interference (RNAi) of PI3K and
chemical inhibitors against PI3K and Akt.
Human NSCs were transfected with vectors containing short
hairpins (shRNAs) that target either the p110a or p110b catalytic
subunits of PI3K. Three days later, hNSCs were primed for four
days with FL, followed by three days in B27 differentiation media.
Semi-quantitative RT-PCRs showed that p110a shRNA de-
creased the expression p110a by 39%, which correlated with a
77% increase in HB9 mRNA (Fig. 2A). Interestingly, a significant
knockdown of p110b RNA by shRNA had no effect on HB9 levels
(Fig. S1A). Thus, PI3K activity, particularly the p110a subunit,
negatively influenced the expression of HB9 in hNSCs. To verify
these RNAi results, hNSCs were treated with a specific PI3K
inhibitor, LY294002 at various concentrations (1 to 25 mM) based
on its IC50 (1.4 mM). Addition of the inhibitor at 1 mM during all 4
days of FL priming did not change the overall morphology of
hNSCs (Fig. 2B), but resulted in an 80% increase in HB9 mRNA
expression (Fig. 2C). Similar results were also seen with 0.2 mM
LY294002 (data not shown). However, higher doses of LY294002
(5 and 25 mM) resulted in decreased HB9 expression, which could
be due to toxic effects of excess LY294002 as indicated by the
WST-1 cell viability assay (Fig. S1B). Cells treated with another
PI3K inhibitor, wortmannin, also displayed an increase in HB9
mRNA (Fig. S1C), which was accompanied by a decrease in the
phosphorylation of Akt at Ser473 (a PI3K downstream target) (Fig.
S1C) and a reduction of phosphorylated GSK3b-Ser9. Together,
these data demonstrate that PI3K activation reduces HB9
expression in hNSCs.
We then investigated the effect of inhibiting the PI3K
downstream target, Akt, during FL priming. Akt inhibitor VIII
at 0.5 mM significantly increased the expression of HB9 by 1.2-fold
(Fig. 2D). Akt inhibitor V also caused a dose-dependent
enhancement of HB9 expression, albeit statistically insignificant
(Fig. S1E). These data suggest that the observed effect of PI3K
inhibition on HB9 was probably due to the subsequent Akt
inhibition. To confirm that the higher PI3K and Akt activation
levels in ELL were responsible for the decreased HB9 transcripts,
we applied the same inhibitors used for FL during ELL priming.
Noticeably, the base-line expression of HB9 in ELL-primed cells
(around 35–55 units, Fig. 2F–G) was much lower than that in FL-
primed (above 100 units, Fig. 2C–D), confirming the inhibitory
role of EGF in motor neuron differentiation as we reported
previously [9]. Higher concentrations (5 mM) of LY294002 was
required to increase HB9 expression by 1.1-fold (Fig. 2F), along
with significant changes of cell morphology and migration pattern
that resembled what was observed in FL-primed cells (Fig. 2E).
Furthermore, Akt inhibitor VIII also caused an increase of HB9 in
ELL cells (Fig. 2G). The differential doses of LY294002 needed to
enhance HB9 gene expression under different priming conditions
correlated well to their effects on blocking Akt activities. As shown
in Fig. S1F–G, the basal level of phosphorylated Akt (pAkt) in FL
was lower than that of ELL-primed cells. One mM of LY294002
sufficiently reduced further the Akt phosphorylation in FL cells,
whereas 5 mM was required to produce a similar effect in ELL-
primed cells. There were no changes in the levels of total Akt
among different treatments (Fig. S1H).
PI3K/Akt-mediated decrease of HB9 expression correlates
with an increase of GSK3b Ser9 phosphorylation
To further understand how PI3K/Akt inhibition increased
mRNA levels of HB9, we exposed cells primed in either ELL
(Fig. 3A) or FL (Fig. 3B) to the PI3K inhibitor LY294002 or the
Akt inhibitors V or VIII, and analyzed the phosphorylation status
of GSK3b Ser9, a major downstream target of Akt. After
40 minutes of priming, proteins were extracted for Western blot
analyses. As expected, all the inhibitors decreased the phosphor-
ylation of GSK3b Ser9 (Fig. 3A–B), thus increasing GSK3b
activity. We also analyzed the MN differentiation pattern of these
cells. Human NSCs were subjected to either ELL or FL priming
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media. In the control groups, there were very few ELL-primed
cells with strong HB9 immunoreactive labeling, while most of FL
cells (over 70%) were strongly labeled with HB9 (Fig. 3C).
Treating ELL- or FL-primed cells with LY294002 resulted in
higher numbers of HB9
+ cells and of MNs (as assessed by the
coexpression of a pan-neuronal marker, microtubule-associated
protein 2 or MAP2, and the MN specific marker HB9, Fig. 3C).
Cell counts (Fig. 3D) confirmed that the numbers of total neurons
(MAP2
+) and of specific MNs (HB9
+/MAP2
+) increased after
LY294002 treatment for 4 days in both ELL and FL groups.
Prolonged treatment with LY294002 for 6 days increased the
percentage of MAP2
+ cells in both groups without changes in
HB9
+/MAP2
+ MNs (Fig. 3D).
GSK3b activation is required for MN differentiation from
hNSCs
Since inhibiting the PI3K/Akt cascade resulted in decreased
phosphorylation of GSK3b Ser9 and increased MN differentiation
from hNSCs, we then asked if the increase in HB9 expression was
due to the increase in GSK3b activity. To this end, we exposed
hNSCs to the GSK3b inhibitors, lithium and GSK3b-inhibitor
VIII, during FL priming; and found that both inhibitors decreased
HB9 (Fig. 4A). Lithium at 3–4 mM and 2 mM GSK3b-inhibitor
VIII reduced HB9 by 50% and 94%, respectively, without causing
cytotoxicity (Fig. S1B). Furthermore, we used a lentiviral vector
containing a short hairpin for GSK3b (shGSK3b). Two to three
days after exposure to shGSK3b at the multiplicity of infection
(MOI) of 1, hNSCs were primed with FL for four days and then
differentiated for three days in B27, the time point exhibiting the
peak HB9 mRNA expression based on our previous report [9].
Semiquantitative RT-PCRs showed that, comparing to the vector
control, shGSK3b significantly decreased the expression of
GSK3b by 44% and reduced the expression of HB9 by 24%
(Fig. 4B).
To determine whether increased GSK3b activity resulted in an
enhancement of HB9 expression, we engineered a lentiviral vector
(LVcaGSK3b) (Fig. 4C) containing a constitutive active mutant
Figure 1. FGF or EGF priming exhibits different temporal patterns of signal activation in hNSCs. (A–B) Representative phase contrast
microscope images show hNSCs primed in either FL (A) or ELL (B) for 4 days. Scale bar=25 mm. (C–D) Temporal patterns of signal phosphorylations in
FL-primed vs. ELL -primed hNSCs at different time points assessed by Western blot analyses. Densitometric values, depicted as a ratio of the
phosphorylated form over total amount of the specific protein, are plotted for phospho-Akt Ser473 (C) and phospho-GSK3b (Ser 9) (D). Data are
presented as mean 6 SEM (n=3); * p,0.05, two-way ANOVA.
doi:10.1371/journal.pone.0023414.g001
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23414Figure 2. Blocking PI3K/Akt signaling by RNAi or inhibitors enhances HB9 mRNA expression in hNSCs. (A) Effect of PI3K knockdown on
HB9 expression in hNSCs. Cells were transfected with either an empty pLK0.1 vector (control) or with pLK0.1 containing DNA coding for a shRNA
targeting the p110a catalytic subunit of PI3K (shP110a). Semi-quantitative RT-PCRs showed that shP110a decreased p110a and increased HB9
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promoter [GAL4 response element (5XRE)], which is regulated by
the synthetic RSL1 ligand when two other proteins (the
RheoReceptor-1 and activator) are also present. A stable cell line
of hNSCs was first created by transfecting cells with the
RheoSwitch plasmid pNEBR-R1 containing RheoReceptor-1
and RheoActivator. The efficiency of this RheoSwitch inducible
system was tested in hNSCs by transfecting these cells with a
plasmid containing the Gaussia princeps secreted luciferase (GLuc)
reporter under the control of the 5XRE promoter. As shown in
Fig. S2, the hNSC cell line secreted negligible luciferase in the
absence of RSL-1, while adding RSL-1 increased the secretion by
more than 100-fold, indicating the RheoSwitch inducible system
was highly efficient with minimal leakage. The same cell line was
then transduced with LVcaGSK3b at the MOI of 1. RSL1 ligand
lead to a significant increase of GSK3b transcription in FL, and to
an enhancement of HB9 expression in both FL (60%, p=0.059)
and ELL (1.2 fold) groups (Fig. 4D). Consequently all these data
suggests that the fact that FL priming increases HB9 levels whereas
ELL priming decreases its expression could be explained, at least
in part, by their differential effects on GSK3b activity.
Manipulation of PI3K/Akt/GSK3b affects the expression of
other MN lineage-related transcription factors
Besides HB9, we also analyzed the effect of inhibiting the PI3K/
Akt/GSK3b pathway on the expression of other MN-related
transcription factors, such as Olig2, Isl1 and Ngn2. Olig2 is an
early transcription factor for the MN-oligodendrocyte cell lineage.
It is required for the expression of other early MN transcription
factors such as Ngn2 and Lhx3, but antagonizes the premature
expression of later transcription factors such as HB9. Isl1, although
also expressed in interneurons, is a LIM homeodomain transcrip-
tion factor that directly sits on the HB9 promoter and activates its
transcription. FL priming is also capable of fostering the
expression of these transcription factors. Immunofluorescent
staining revealed that many of the hNSCs, after FL-priming and
differentiation in B27 for nine days, became MAP2
+ Isl1
+ or
Tuj1
+Ngn2
+ neurons (Fig. 5A).
Semiquantitative RT-PCR analyses showed that Olig2 levels
were not affected in the wortmannin- and Akt inhibitor VIII-
treated groups (data not shown). Isl1 expression, on the other
hand, displayed a similar pattern as HB9, i.e., increasing in levels
when cells were exposed to either wortmannin or Akt inhibitor
VIII (Fig. 5B). In addition, we found that inhibition of GSK3b
with GSK3b-inhibitor VIII decreased both Olig2 and Isl1
(Fig. 5C–D). No changes were detected in the expression levels
of Otx2 (a forebrain and midbrain transcription factor) and Pax6
(a transcription factor for the ventral spinal cord) in primed hNSCs
after treatment with these PI3K/Akt inhibitors (data not shown).
PKC-f activation is necessary for MN differentiation from
hNSCs
The above studies indicated that activation of PI3K, via Akt,
negatively regulates MN differentiation from hNSCs. Since PI3K
also activates other targets, including PKC-f (protein kinase C
zeta, an atypical PKC) by phosphorylating it at Thr410 [21], we
asked whether the status of PKC-f activation affected MN fate
determination. Unlike Akt (Fig. 1C), phosphorylation of PKC-f at
Thr410 exhibited an increased temporal pattern of activation in
the FL group as compared with the ELL group (Fig. 6A). To
determine whether PKC-f activity was required for the FL
induction of HB9, we exposed hNSCs to the PKC-f specific
inhibitor (myristoylated pseudosubstrate inhibitor or PS, Table S1)
during FL priming. Three mM PS dramatically decreased the
migratory capacity of hNSCs, showing the cells stayed near the
center of the spheres (Fig. 6B), as wells as reduced the HB9
transcripts (Fig. 6C).
Next, we tested whether there was a connection between PKC-f
and Akt/GSK3b with respect to HB9 transcription. Interestingly,
blocking the activity of PKC-f by PS increased phosphorylation of
both Akt Ser473 and GSK3b Ser9 (Fig. 6D–E), suggesting that
maintaining PKC-f activity is required to suppress the high-level
activation of Akt and subsequently allows GSK3b to function
properly in MN differentiation. Similarly, we assessed the
phosphorylation status of PKC-f after priming hNSCs in FL for
3 days in the presence of PI3K or Akt inhibitors. Western blot
analyses showed that 1 mM Wortmannin (a concentration
enhanced HB9) did not change the level of PKC-f phosphoryla-
tion at Thr410 (Fig. 6F). In contrast, inhibition of Akt activity by
Akt inhibitor VIII significantly increased phosphorylated PKC-f
(Fig. 6F). Taken together, these results identified a negative
interplay between PKC-f and Akt in FL-primed hNSCs, and
showed that the required activity of PKC-f for HB9 expression
was PI3K-independent.
Besides the atypical PKC-f, the PKC family comprises other
isozymes grouped into classical and novel PKCs (cPKCs and
nPKCs respectively). FGF and EGF can also activate these PKCs
through phosphorylation of phospholipase C gamma (PLC-c)
[22]. Analysis of the temporal pattern of activation of these kinases
showed no differences between FL and ELL when using a pan
antibody against all phosphorylated PKCs (data not shown).
Furthermore, a specific PLC-c inhibitor (U73122) and an inhibitor
for both classical and novel PKC (GF 109203X, Table S1), did not
affect HB9 expression in FL-primed cells (data not shown). Thus,
the activation of other conventional and novel PKC isoforms
downstream of PLC-c does not seem to contribute to FGF-
induced HB9 expression, whereas PKC-f activity is required for
this induction.
Blocking PI3K/Akt activity increases MN differentiation
from transplanted hNSCs in vivo
The above studies suggested a negative impact of PI3K/Akt
activation on MN specification from human fetal NSCs in vitro.W e
then investigated whether blocking the PI3K signals could
enhance MN differentiation from the hNSCs grafted into adult
rat spinal cords. Human NSCs treated with or without 1 mM
LY294002 (LY) during FL priming were injected into the L4
ventral horn (n=9 per group). To track the grafted cells in rat
spinal cord, hNSCs were pre-labeled with enhanced green
fluorescent protein (eGFP) via recombinant adeno-associated viral
transcripts. (B–D) Effect of PI3K/Akt inhibition on hNSCs primed for 4 days in FL plus DMSO (FL or Control). Cells were treated with inhibitors for PI3K
(LY294002, 1–25 mM) or Akt (Akt inhibitor VIII, 0.5 mM). Treatment with LY294002 at 1 mM (B–C) or Akt inhibitor VIII at 0.5 mM (B and D) did not change
the cell morphology (B), but increased HB9 transcripts compared with the control group (C–D). (E–G) Effect of PI3K/Akt inhibition on hNSCs primed
for 4 days in ELL plus DMSO (ELL or Control). (E) Representative images show that, in the presence of these inhibitors, hNSCs lost the spindle and/or
radiated cell shape seen in the ELL control. Treatment with LY294002 (5 mM) (F) and Akt inhibitor VIII (0.5 mM) (G) increased HB9 transcript levels
compared with the control group. Densitometric values were normalized to GAPDH internal controls and are presented as mean 6 SEM (n=3); *
p,0.05, ** p,0.01; one-way ANOVA or t test. Scale bars=25 mm.
doi:10.1371/journal.pone.0023414.g002
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23414Figure 3. Inhibition of PI3K/Akt activity reduces phosphorylation of GSK3b while increases HB9 motor neuron differentiation. (A–B)
Effect of PI3K/Akt inhibition on GSK3b phosphorylation in hNSCs primed for 40 minutes in either ELL (A) or FL (B). Cells were treated during priming
with the PI3K inhibitor LY294002 or the Akt inhibitors V or VIII, and analyzed by western blot densitometry for the phosphorylation status of GSK3b at
Ser9. Phospho GSK3b at Ser9 (pGSK3b-S9) values were normalized to total GSK3b (tGSK3b). In both ELL and FL primed groups, all inhibitors decreased
GSK3b Ser9 phosphorylation as compared with DMSO controls (mean 6 SEM; n=3; * p,0.05, ** p,0.01, *** p,0.001, one-way ANOVA). (C–D) Effect
of PI3K inhibition on motor neuron differentiation. Cells were treated with either DMSO (control) or 1–5 mM LY294002 for four days during priming (C
and LY4d in D) or 4-day priming plus 2-day B27 differentiation (LY6d in D). Representative images are shown in (C) for immunostaining using
antibodies against HB9 (red) and microtubule-associated protein 2 (MAP2; green). Nuclei were counterstained with DAPI (blue). Scale bars=50 mm.
Quantitative analyses show that LY294002 treatments increased the percentages of HB9
+, MAP2
+ and double-labeled (HB9
+ MAP2
+) motor neurons in
both ELL and FL groups (D). Data are the mean 6 SEM, n=3. ** p,0.01 and *** p,0.001, one-way ANOVA.
doi:10.1371/journal.pone.0023414.g003
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23414Figure 4. GSK3b activation is required for HB9 mRNA expression in hNSCs. (A) Effect of GSK3b inhibition on HB9 expression in hNCSc. Cells
were exposed to the GSK3b inhibitors (lithium and GSK3b-inhibitor VIII) during FL priming for 4 days. Semi-quantitative RT-PCRs showed that FL
priming (control) increased HB9 expression as compared to spheres (* p,0.05, ** p,0.01), while both inhibitors decreased HB9 transcript levels as
compared to vehicle controls (# p,0.05). (B) Effect of GSK3b knockdown on HB9 expression in hNSCs. Cells were transduced with a lentiviral vector
containing a short hairpin that targets GSK3b (shGSK3b), primed with FL for 4 days and then differentiated for 3 days in B27. Semiquantitative RT-
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many grafted cells acquire neuronal characteristics in both dorsal
and ventral horns of the spinal cords at one month post-
transplantation (Fig. 7). Some large neuron-like grafted cells
(green) were found in dorsal horns from both the control group
(Fig. 7A–B) and the LY-treated group (Fig. 7C–D, Fig. S3).
PCRs showed that shGSK3b decreased both GSK3b and HB9 transcripts as compared with the vector control. (C) Schematic illustration of an engineered
inducible lentiviral vector (LVcaGSK3b), which contains RRE (Rev response element), Terminator (SV40 terminator), 5XRE (GAL4 response element),
caGSK3b (constitutive active mutantformof theGSK3b, Ser9Ala), SV40 polyA signal, CPPT (central polypurinetract). (D)Effect of induced overexpression
of constitutively active GSK3b on HB9 expression in hNSCs. An hNSC cell line expressing the RheoReceptor-1 and RheoActivator was transduced with
LVcaGSK3b (LV) and primed in either FL (F+LV) or ELL (E+LV). Treatment with synthetic ligand RSL-1 increases HB9 mRNA. GSK3b or HB9 densitometric
values were normalized to GAPDH internal controls, and are presented as mean 6 SEM; n=3; * p,0.05, ** p,0.01, # p,0.05; one-way ANOVA or t test.
doi:10.1371/journal.pone.0023414.g004
Figure 5. Effect of PI3K/Akt/GSK3b inhibition during FL priming on other motor-neuron linage-related transcription factors. (A)
Representative images of FL-primed and differentiated hNSCs detected by immunofluorescent staining with antibodies against microtubule-associated
protein 2ab (MAP2), Isl1, class III b-tubulin (TuJ1), Ngn2, Olig2. Nuclei are counterstained with DAPI. (B) Effect of PI3K/Akt inhibition on Isl1 mRNA
expression in hNSCs. Cellswere primedfor four days in FL andtreated with inhibitors for PI3K (wortmannin, 1 mM) or Akt (Akt inhibitor VIII, 0.5 mM). Both
treatments increased Isl1 transcripts compared with the control group. Densitometric values were normalized to GAPDH internal controls and are
presented as mean 6 SEM (n=3); ** p,0.01, one-way ANOVA. (C–D) Effect of GSK3b inhibition on Olig2/Isl1 mRNA expression in hNSCs. Cells were
exposed to two doses (1 and 2 mM) of GSK3b-inhibitor VIII (GSK3b-i8) during FL priming for four days. Semi-quantitative RT-PCR showed that this
inhibitor decreased Olig2 (C) and Isl1 (D) transcript levels as compared to controls. Data are mean 6 SEM, n=3, * p,0.05, one-way ANOVA.
doi:10.1371/journal.pone.0023414.g005
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+/choline acetyl-
transferase (ChAT)
+ MNs (12.5%), some in diameter near 50 mm,
in Laminae V–VI (Fig. S3) and VII (Fig. 7D), where there are
either no endogenous ChAT
+ neurons or no ChAT
+ neurons
larger than 25 mm. In contrast, FL-primed cells without LY
treatment expressed neither HB9 nor ChAT (Fig. 7B) in the dorsal
region. In ventral horns, about 55% of GFP-expressing cells were
co-labeled with HB9 and ChAT in animals receiving FL-primed
hNSCs (Fig. 7E and G), while 88.5% of FL-LY-treated hNSCs
became HB9
+/ChAT
+ cells (Fig. 7F–G). Therefore, LY-treatment
significantly increased MN differentiation from grafted hNSCs in
adult rat spinal cord.
Discussion
The present work demonstrated a novel role of the PI3K/Akt/
GSK3b pathway in spinal MN specification from hNSCs in response
to FGF2 or EGF. We showed for the first time that manipulation of this
pathway significantly influenced the fate of hNSCs to become MNs,
both in vitro and after transplantation into adult rat spinal cords.
Figure 6. PKC-f activation is required for HB9 mRNA expression in hNSCs. (A) Temporal patterns of PKC-f phosphorylation in FL-primed vs.
ELL-primed hNSCs at different time points assessed by Western blot analyses. (B) Representative phase contrast images of FL-primed hNSCs treated
with 3 mM PKC-f pseudosubstrate inhibitor (PS) for four days. Note the complete spread of cells into monolayer in the FL-priming group (Control), in
contrast to the limited spread of cells away from spheres in the PS-treated group (PS). Scale bar=20 mm. (C) Effect of PKC-f inhibition on HB9
expression in hNSCs. Semi-quantitative RT-PCR and densitometric analysis show that PS decreases HB9 expression as compared with the control. HB9
values were normalized to GAPDH internal controls. (D–E) Effect of PKC-f inhibition on Akt/GSK3b activity in hNSCs. Cells were FL-primed and treated
with either water (control) or the PKC-f pseudosubstrate inhibitor (PS) for 3 days. Densitometric values are shown for pAkt (D) and pGSK3b-S9 (E). (F)
Effect of PI3K/Akt inhibition on PKC-f phosphorylation in hNSCs. Cells were FL-primed and treated with either DMSO (control), 1 mM wortmannin
(WM) or 0.5 mM Akt inhibitor VIII (AKTin VIII) for 3 days. Data are presented as mean 6 SEM (n=3); * p,0.05, one-way ANOVA or t test.
doi:10.1371/journal.pone.0023414.g006
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PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e23414Stem cells may be a source to replace MNs that are lost in
diseases such as amyotrophic lateral sclerosis and spinal cord
injury. Previously many groups, including ours, have successfully
generated MNs from embryonic or neural stem cells [17]. We
further discovered that priming hNSCs with FGF2-containing
media (FL) potentiated them to become MNs, while priming with
EGF-containing media (ELL) drove hNSCs away from the MN
differentiation path. Instead these ELL-primed cells differentiated
toward glutamate and c-aminobutyric acid (GABA) neuronal
subtypes [9]. As a first step to elucidate how molecular signaling
differences triggered by these two growth factors result in a
different cell fate (i.e. MN), we compared the major canonical
pathways activated by FGF and EGF and found that they share
similar signals, including Ras/MAPK, PI3K/Akt and PLC-c/
PKC [10]. We, therefore, focused on differences in intensity of
phosphorylation of the pathway elements and the duration of this
phosphorylation. Analysis of the temporal patterns of activation
revealed increased activity of Akt (i.e. increased phosphorylation of
Akt Ser473 and its target GSK3b Ser9) during ELL priming as
compared with FL. Since Akt activation by growth factor
stimulation requires PI3K activity [23,24], we blocked PI3K
using RNAi against the PI3K catalytic subunits p110a or p110b.
Knock-down of p110a promoted an increase in HB9 expression,
while RNAi against p110b had no effect on HB9. The latter may
be due to a more prevalent role of p110b in G-protein coupled
receptor than in receptor tyrosine kinase signaling as previously
observed [25]. In addition, applying specific PI3K chemical
inhibitors increased HB9 transcript levels and decreased phos-
phorylation of Akt Ser473. This evidence points towards the
PI3K/Akt pathway being responsible for repressing HB9 expres-
sion. However, PI3K activity affects several other molecules
besides Akt [26]. In order to verify that Akt was actually involved
in the regulation of HB9, we inhibited Akt directly using several
inhibitors, and found that Akt inhibition increased HB9 levels,
which correlated with a decrease in GSK3b phosphorylation at
Ser9, a modification that decreases GSK3b activity. Further
manipulation of GSK3b showed that increased active GSK3b by
expressing its constitutive active mutant form enhanced HB9
expression, whereas inhibitory manipulations of GSK3b by RNAi
or inhibitors decreased HB9, confirming that GSK3b was
required for proper HB9 expression.
Several other transcription factors, such as Olig2, Isl1, and
Ngn2, are also critical in specification of the MN lineage during
development [27–29]. In FL-primed hNSCs, we found that most
of these markers behaved in a similar way as HB9, for example,
Isl1 and Ngn2 levels increased when PI3K/Akt were inhibited.
Moreover, Isl1 and Olig2 were downregulated when GSK3b
activity was decreased. One exception is Olig2, i.e., blocking
PI3K/Akt did not affect the level of Olig2 transcript. A possible
explanation is that Oligo2, unlike Isl1 and HB9, may also be
regulated by other unknown molecules, in addition to the PI3K/
Akt/GSK3b pathway. This makes sense since Olig2 is a critical
transcription factor promoting the development of a common
progenitor lineage that eventually generates both MN and
oligodendrocyte [29]. However, a continuously high level of Olig2
inhibits MN while promotes oligodendrocyte differentiation. Thus,
the lack of effect on Olig2 but increasing Isl1 and Ngn2 by
inhibiting PI3K/Akt would act in concert to facilitate MN
generation.
All these data together support a model in which PI3K and Akt
activation by the stimulated EGFR (in ELL priming) is higher than
the activation caused by the stimulated FGFR (in FL priming)
(Fig. 7H). Higher PI3K and Akt activities result in a decreased
GSK3b activity, which leads to a decreased expression of MN
markers. In other words, two different growth factors, FGF2 and
EGF, via their different effects on the activation of the PI3K/Akt/
GSK3b pathway, result in differential MN specification of
cultured hNSCs. This model agrees with a previous in vivo mouse
study, which showed that for MN differentiation to proceed, Ngn2
had to be phosphorylated on two key serine residues, S231 and
S234, and that GSK3b was required for this phosphorylation [30].
Activation of the PI3K pathway either positively or negatively
contributes to the differentiation of various types of cells, including
immune, intestinal or muscle cells [31–34]. We are the first to
demonstrate a negative role of PI3K/Akt/GSK3b in mediating
neuronal differentiation. Noticeably hNSC neurospheres are
heterogeneous in nature, i.e. containing both stem cells and
progenitors at various stages. They are extremely sensitive and
respond differently to external cues. All these could result in
variations observed among different experiments [9], and possibly
contribute to the slight changes of some of the signaling molecules
characterized in this study. On the other hand, the moderate
differences in the levels of Akt and GSK3b phosphorylation
between FL and ELL result in significant changes of MN
differentiation from the heterogeneous hNSCs, as shown both by
the analyses of HB9/Map2 double-labeled neurons here and of
the HB9/ChAT neurons in our previous report [9]. This is not
totally surprising since the fine tuning of PI3K activation is most
likely critical for eliciting its multiple roles in cell proliferation,
survival or differentiation. Given apparent cell death accompanied
with cell differentiation following withdrawal of growth factors,
and particularly after Akt inhibition, we speculate that motor
neuron differentiation occurs to some extent at the expense of cell
survival. Relationships among cell proliferation, death/survival,
and neuronal differentiation are certainly granted for future
investigation.
The question is then whether the PI3K/Akt/GSK3b pathway is
the sole player to determine MN fate specification. So far, we
excluded out two other canonical pathways shared by FGF and
EGF, MAPK [9] and PLC-c here, since blocking these signals did
Figure 7. Blocking PI3K signaling increases motor neuron differentiation in hNSCs grafted into adult rat spinal cords. (A–B)
Representative confocal images of enhanced green fluorescent protein (eGFP)-labeled hNSCs in the dorsal horn of the adult rat spinal cord L4 at 1
month post transplantation. White curve outlines the dorsal horn in (A). (B), higher magnification images of the inset in (A). Grafted hNSCs with FL-
priming alone did not co-label with choline acetyltransferase (ChAT, red) or HB9 (blue). (C–D) FL-primed hNSCs, when treated with LY294002,
differentiated into Hb9/ChAT immunoreactive motor neurons in the Lamina VII of rat spinal cord. (D), higher magnification images of the inset in (C).
(E) FL-primed hNSCs differentiated into ChAT
+/Hb9
+ motor neurons in the ventral horn. (F) FL-primed and LY294002-treated hNSCs differentiated into
Hb9
+/ChAT
+ motor neurons in the ventral horn. (G) Cell counts show a significant increase of the percent of ChAT
+ neurons from the grafted eGFP
+
hNSCs treated with LY294002 when compared to the control. Scale bars=50 mm. C, central canal. Arrow, grafted eGFP
+ hNSCs become Hb9
+/ChAT
+
motor neurons. Arrowhead, endogenous Hb9
+/ChAT
+ motor neurons. (H) Proposed model for differential effects of FGF and EGF on motor neuron
differentiation from hNSCs. FGF and EGF, via activating their receptor tyrosine kinases (FGFR and EGFR respectively), differentially affect the PI3K/Akt/
GSK3b pathway. FGFR-induced PI3K/Akt activation is lower than EGFR, which results in a lower phosphorylation of GSK3b at Ser 9 with increased
activity. Higher GSK3b activity leads to an enhanced transcription of HB9, presumably via Ngn2 phosphorylation/activation. PKC-f cross-talks with Akt
through mutual inhibition, which then modulates GSK3b activity and HB9 expression.
doi:10.1371/journal.pone.0023414.g007
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additional to these shared pathways, EGF is known to also
activate the STAT3 pathway. However, STAT3 inhibition
exhibited little or no effect on HB9 expression in EGF-primed
cells (unpublished observations). It is noticeable that the phos-
phorylation patters of Akt and GSK3b, as well as their activity
inhibitions, are not exactly correlated to each other. One
explanation is that even though higher phosphorylation of AKT
usually translates into higher phosphorylation of GSK3b, these
changes may not always be proportional as other pathways (e.g.
Wnt) also affect the final phosphorylation state of GSK3b in a
given cell. Along this line, whether and how Wnt and/or other
unknown signaling pathway(s) are also involved in MN specifica-
tion remains to be determined.
To begin exploring other signaling molecules, we found that PKC-f
was also required for HB9 expression in hNSCs. Interestingly, both
PKC-f and Akt were previously reported downstream effectors of
PI3K [21,35]. However, in hNSCs, blocking PKC-f or Akt resulted in
opposite effects on HB9 mRNA expression, and the phosphorylation of
PKC-f was PI3K-independent. One possibility is that other signaling
molecule(s) may be involved in activating PKC-f. Alternatively, PKC-f
may have constitutive activity that is resistant to the inhibition of PI3K
as indicated in other cell types [36,37]. This basic level of PKC-f
activation may be required for HB9 expression in FL-primed hNSCs,
whereas the high level of Akt activation in ELL-primed cells negatively
regulates the activity of PKC-f and thus reduces HB9. On the other
hand, we found that PKC-f also inhibited Akt activation. Thus, the
crosstalk between Akt and PKC-f through mutual inhibition of each
other may fine-tune the levels of PI3K/Akt/GSK3b activation, which
influence the fate of MN differentiation (Fig. 7H).
Defining a negative role of the PI3K/Akt/GSK3b in spinal MN
specification from hNSCs allowed us to obtain nearly a pure
population of HB9
+ cells in vitro by inhibiting PI3K activity. The
generation of a large quantity of HB9 MNs from hNSCs within
only two weeks, much shorter than needed for derivations from
embryonic stem cells [38], is important for creating a reliable and
efficient in vitro supply of human MNs for pathological studies and
drug screen. More importantly, combination of FGF priming
together with PI3K inhibition significantly increased the percent-
age of hNSCs becoming HB9
+ and ChAT
+ MNs after
transplantation into adult rat spinal cord. Previously, we found
that FGF-primed hNSCs became MNs in a region-specific
manner, i.e., only in the ventral horn of spinal cord [3,39]. In
this study, however, we observed large HB9
+/ChAT
+ MNs from
grafted hNSCs in the Lamina V, VI and VIII regions that are
reported to lack endogenous ChAT
+ neurons larger than 25–
36 mm [40,41], indicating that manipulation of the PI3K signaling
pathway enables grafted hNSCs to ignore the host environmental
cues/limitations. This raises hope that we may be able to find a
way to induce endogenous neural stem cells to become MNs in
injured or degenerated spinal cords that normally inhibit MN
differentiation. Following injury, most tissues tend to enter a repair
process in which the PI3K/Akt pathway is critical for enhancing
proliferation and survival of various cell types, including NSCs and
neurons [42,43]. NSCs are known to exist in the ependymal layer
of the central canal of adult spinal cords [44,45], but seem to lose
their capability to become MNs after spinal cord injury or
degeneration. A possible explanation, as indicated by our
observation of the negative effect of PI3K/Akt/GSK3b on MN
specifications, is that insults trigger the spinal cord cells to elevate
their survival mechanisms through PI3K signaling at the expense
of inhibiting specific MN differentiation. Questions remain to be
answered as whether and how manipulating the PI3K pathway
could induce adult spinal cord NSCs to become MNs, as a way of
self repair in patients suffering from spinal cord injury or MN
diseases.
Materials and Methods
A detailed description of the materials and methods is found in
the online Supporting Information – Supplemental Methods S1.
Ethics statement
All animal studies were carried out in strict accordance with the
ARRIVE guidelines. The protocol (#9910051) was approved by
the Institutional Animal Care and Use Committee at the
University Of Texas Medical Branch Galveston. All surgeries
were performed under isoflurane anesthesia with all efforts made
to minimize suffering.
Human neural stem cell culture, priming and
differentiation
Human fetal cortical neural stem cells (hNSCs) were propagated
as neurospheres in the presence of EGF, FGF2, and LIF as
previously described [2]. For priming, cells were allowed to attach
to laminin-precoated surface under either FGF2/heparin/laminin
(FHL), EGF/LIF/laminin (ELL), or N2/laminin (N2). For in vitro
differentiation, primed cells were cultured in B27 containing
media.
Inhibitor treatments and cell viability assays
Human NSCs were treated with specific inhibitors at different
doses (Table S1) for various times as indicated in the Results. Cell
viability was assessed using a commercially available WST-1 kit
according to the manufacturer’s instruction (Roche Applied
Science, Indianapolis, IN, USA).
Short hairpin RNA knockdown and induced transgene
overexpression
Sigma MissionH shRNA plasmids were screened and used to
knockdown the expression of human p110a, p110b or GSK3b
genes in hNSCs through Nucleofection or Lentiviral (LV)
transduction as described in Supplemental Experimental Proce-
dures. Inducible LVcaGSK3b was constructed based on
pLK0.1puro (Sigma), HA GSK3b S9A pcDNA3 (AddGene Inc.,
Cambridge, MA, USA) and RheoSwitch Mammalian Inducible
Expression System (New England Biolabs, Ipswich, MA, USA).
Constitutively active GSK3b was over-expressed in hNSCs
following LV vector transduction and RheoSwitch Ligand 1
(RSL-1) treatment as described in Supplemental Methods S1.
Animals and spinal cord transplantation
The ARRIVE guidelines were followed for the animal
experiments. FHL-primed hNSCs, with or without PI3K inhibitor
LV294002 treatment, were stereotaxically grafted into the L3-4
spinal cord of adult male Sprague Dawley rats according to our
previous description [3,39,46] and Supplemental Methods S1.
RNA analyses
Total RNA was extracted and subjected to semiquantitative
RT-PCR as previously described [9]. Primer sequences for human
GAPDH, HB9, Olig2, Islet1, p110a, p110b and GSK3b are listed
in Table S3.
Western blot analyses
Proteins were extracted at various time points after priming, and
subjected to Western blot analyses as described in Supplemental
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Table S2.
Immunostaining and imaging
Fixed cells or tissue sections underwent immunofluorescent
staining using antibodies against HB9, Islet1, Olig2, Ngn2, MAP2
or ChAT as described in Supplemental Experimental Procedures
and Table S2. Images were acquired with either Nikon 80i
epifluorescent microscope or Nikon D-Eclise C1 confocal system.
Statistical analyses
All analyses included at least three independent experiments
unless otherwise stated. For immunofluorescent staining on
cultured cells, specific labeling was counted from 10 randomly
selected fields of three or four coverslips for at least 1000 total cells
per treatment. For in vivo studies, at least 200 GFP-labeled hNSCs
in each group of five rats per group were counted and percentages
of GFP/ChAT double-labeled cells were calculated. All statistical
analyses were performed using Student’s t test, one-way or two-
way ANOVA with the aid of GraphPad Prism software
(GraphPad Software, Inc. CA, USA).
Supporting Information
Figure S1 Effect of manipulating the PI3K/Akt/GSK3b
pathway on HB9 levels and cell viability. (A) Effect of PI3K
knockdown on HB9 expression in hNSCs assessed by semi-
quantitative RT-PCRs. Cells were transfected with either an
empty pLK0.1 vector (control) or with pLK0.1 containing DNA
coding for a shRNA targeting the p110b catalytic subunit of PI3K
(shP110b). shP110b decreased p110b but had no effect on HB9
transcripts. GAPDH is shown as an internal control. (B) Cell
viability in FHL-primed hNSCs assessed by WST-1 four days after
treatment with various inhibitors (n=6). Control, DMSO; WM,
wortmannin; LY, LY294002; AKTi5, Akt inhibitor V; AKTi8,
Akt inhibitor VIII; Lith, lithium acetate; GSK3i8, GSK3b
inhibitor VIII; PS, myristoylated PKC-f pseudosubstrate inhibitor.
(C) Effect of PI3K inhibition on HB9 mRNA expression in hNSCs
assessed by semi-quantitative RT-PCRs. Cells were primed for
four days in FHL and treated with the PI3K inhibitor wortmannin
(WM, 1 mM). Wortmannin increased HB9 transcripts as com-
pared with the DMSO control. HB9 values were normalized to
GAPDH internal controls. (D) Effect of wortmannin (WM) on
phosphorylation of Akt in hNSCs assessed by western blot
analyses. Cells were primed for 1 day in FHL and treated with
the PI3K inhibitor wortmannin (WM, 1 mM). Densitometric
values are shown as a ratio of phosphorylated Akt Ser473 (pAkt)
over total Akt protein (n=3). (E) Effect of Akt inhibition on HB9
mRNA expression in hNSCs assessed by semiquantitative RT-
PCR analyses. Cells were primed for four days with FHL and
treated with various doses of Akt inhibitor V (AKTinh V) (n=3).
(F) and (G) Differential effects of LY294002 at different doses on
the phosphorylation of Akt (pAkt) in hNSCs primed with FL and
ELL, respectively (n=3). (H) The levels of total Akt remain
unchanged in hNSCs under different treatments (n$3). All data
are presented as mean 6 SEM, * p,0.05, ** p,0.01,
*** p,0.001, Student’s t test or ANOVA with post tests.
(EPS)
Figure S2 Efficient induction of transgene expression by
a RheoSwitch inducible system in hNSCs. A cell line of
hNSCs, stably transfected with the pNEBR-R1 plasmid containing
theRheoReceptor-1 and RheoActivator genes,was transfectedwith
the pNEBR-X1GLuc vector and stimulated with the RSL-1 ligand
24 h and 48 h after transfection. Four days after the first RSL-1
exposure, conditioned media from these cells was tested for
luciferase activity. Treatment with RSL-1 significantly increased
the amount of secreted luciferase as compared to the RSL-1
unstimulated control group. Luciferase activities are expressed in
arbitrary units, Random luminometer units, and presented as mean
6 SEM; n=3, *** p,0.001.
(PDF)
Figure S3 Grafted hNSCs with PI3K inhibition ignore
environmental cues and differentiate ectopically into
large motor neurons in the dorsal horn of adult rat
spinal cords. (A) A representative low magnification confocal
image of eGFP-labeled hNSCs becoming choline acetylcholine
(ChAT) immunoreactive cells in the Lamina V–VII one month
after transplantation into rat spinal cords. Nuclei are counter-
stained with DAPI. C, central canal. (B–D) Higher magnification
images of the inset in (A). Arrow, grafted eGFP
+ hNSCs are
immunofluorescently stained with ChAT
+ antibodies. Arrowhead,
endogenous ChAT
+ interneurons. Scale bars=50 mm.
(EPS)
Table S1 List of the inhibitors.
(PDF)
Table S2 List of antibodies.
(PDF)
Table S3 List of primers.
(PDF)
Methods S1 Human neural stem cell expansion, priming and
differentiation. Short hairpin RNAs and Nucleofection. Inducible
Lentiviral vector construction, packaging and transduction.
Animals and transplantation. RNA analysis. Western blot
analyses. Immunostaining and imaging.
(DOC)
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